X4 Pharmaceuticals Inc. logo

X4 Pharmaceuticals Inc.

XFOR | NASDAQ
Chart Builder DCF Calculator
$3.44
-$0.06 (-1.57%)
Sep 22, 2026, 12:48 PM ET · Market open

Market Data

Market Cap
$329.65M
Enterprise Value
$122.14M
Beta
0.35
Average Volume
642.91K
Shares Outstanding (Diluted)
126.34M
Shares Change YoY
1604.36%
Institutional Ownership
71.61%
Exchange
NASDAQ
ISIN
US98420X2027

Price Performance

Price Change 1M
-12.5%
Price Change 3M
-12.5%
Price Change 6M
-14.4%
Price Change YTD
-10.0%
Price Change 1Y
3.5%
Price Change 3Y
-88.8%
Price Change 5Y
-97.9%
1M CAGR (ann.)
-24.6%
1Y CAGR (ann.)
8.0%
5Y CAGR (ann.)
-53.0%
All-Time CAGR
-52.5%

Valuation

PE Ratio
-2.92
Forward PE
N/A
PEG Ratio
-0.01
Forward PEG
-0.37
PS Ratio
20.80
Forward PS
28.50
PB Ratio
2.12
P/FCF Ratio
-3.94
P/Adj. FCF Ratio
-3.57
P/OCF Ratio
-5.30
EV/Sales
7.71
EV/EBIT
-1.50
EV/EBITDA
-1.54
EV/FCF
-1.46
Earnings Yield
-34.3%
FCF Yield
-25.4%
Adj. FCF Yield
-28.0%

Financial Health

Net Cash
$207.5M
Total Debt
$465K
Cash & Short-Term Investments
$207.97M
Total Assets
$253.06M
Current Ratio
11.30
Quick Ratio
11.02
Debt / Equity Ratio
0.50
Debt / EBITDA
-0.01
Debt / FCF
-0.01
OCF / Debt
-222.23
Interest Coverage
-10.06
Altman Z-Score
-1.52
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
81.2%
Operating Profit Margin
-554.7%
EBITDA Margin
-501.8%
Net Profit Margin
-568.8%
FCF Margin
-528.4%
Adj. FCF Margin
-582.2%
SBC / Revenue
53.8%
SBC Impact (per share)
-10.2%

Returns

Return on Assets
-35.6%
Return on Equity
-63.0%
Return on Invested Capital
-37.5%
Return on Capital Employed
-37.6%
Return on Tangible Assets
-40.5%

Historical Growth (CAGR)

Revenue CAGR 3Y
46.6%
Revenue CAGR 5Y
65.5%
Revenue CAGR 10Y
49.3%
EPS CAGR 3Y
-41.6%
EPS CAGR 5Y
73.7%
EPS CAGR 10Y
37.5%
FCF CAGR 3Y
14.1%
FCF CAGR 5Y
-5.3%
FCF CAGR 10Y
-16.9%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
13
EPS Growth Next 3Y
29.4%
Revenue Growth Next 3Y
137.2%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
-$0.19
EPS Growth Est (next Q)
-72.5%
Revenue Est (next Q)
$2.3M
Revenue Growth Est (next Q)
30.3%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$11.50
Price Target Upside
228.6%

Cash Flow

Operating Cash Flow
$-103.34M
Free Cash Flow
$-83.74M
Adj. Free Cash Flow
$-92.27M
FCF Per Share
-$0.66
OCF Per Share
-$0.66
OCF/S Ratio
-528.4%

Income Statement

Revenue
$15.85M
Gross Profit
$12.87M
Operating Income
$-87.91M
EBITDA
$-79.52M
Net Income
$-90.14M
EPS (Diluted)
-$1.20
Revenue / Employee
$352.16K
Profit / Employee
$-2M
Employees
45

© 2026 bestshares.com. All rights reserved.